PERTH, Australia
and BILLERICA, Mass.,
Sept. 20, 2019
/PRNewswire/ -- Murdoch University and Bruker (Nasdaq: BRKR) today
announced a strategic collaboration that will help transform the
prevention and diagnosis of disease and personalised health around
the world. The Murdoch-Bruker collaboration will play a key role
within the Australian National Phenome Centre (ANPC)1,
the international centre of expertise for metabolic
phenotyping. The ANPC has recently been established under the
leadership of Murdoch University Pro Vice Chancellor for Health
Sciences and international pioneer in phenomics Professor
Jeremy Nicholson, and distinguished
2018 Western Australia Premier's
Fellow in Phenomics, Professor Elaine
Holmes.
Equipped with various Bruker nuclear magnetic resonance
(NMR) and various mass spectrometry (MS) phenomics solutions, the
ANPC will enable researchers to examine the complex interactions of
genes, the environment and lifestyle on human metabolic health. The
ANPC will be a critical platform for the Western Australian Health
Translational Network (WAHTN) and will work closely with major
hospitals, universities and medical research institutes. It is an
affiliate of the International Phenome Center Network (IPCN),
founded under the leadership of Professor Nicholson.
Murdoch University Deputy Vice Chancellor for Research and
Innovation, Professor David
Morrison, said the University welcomed its alliance with
Bruker, and stated: "The launch of the ANPC is the culmination of
many years of hard work and the strategic vision of leaders across
Murdoch University who recognised the significance of phenomics
research, and supported the establishment of an international
centre of expertise in this area."
"We're thrilled that Bruker, a world leading manufacturer
of research equipment, will contribute its technological and
research expertise to help us improve health outcomes around the
world," added Professor Nicholson. He continued: "Phenomics is a
key next step in expanding the boundaries of our knowledge of human
health and the causes and prevention of disease. The strategic
alliance between Murdoch University and Bruker enhances the
valuable work of the ANPC by bringing state-of-the-art instruments
and experienced researchers in this space to Western Australia. It reflects the growing
focus and investment in precision medicine in the Asia Pacific region and will help us to
transform how long and how well people live, not just in
Australia, but around the
world."
Murdoch University now has multiple state-of-the-art
Bruker phenomics solutions, including seven AVANCE® IVDr
600 MHz NMRs, one NMR FoodScreener™, an ESI & MALDI MRMS
(Magnetic Resonance Mass Spectrometry) system for high-throughput
flow-injection analysis (FIA) MRMS workflows, twelve impact-II QTOF
and two timsTOF™ systems. Bruker provides extensive applications,
service and R&D support to the ANPC for support, training,
beta-testing and the validation of assays and tools
developed.
The AVANCE IVDr systems include clinical research software
for the quantification of plasma and urine. This IVDr software
suite enables Murdoch to leverage Bruker's standardized automated
workflow for bodyfluid QC, quantification and analysis, which is
essential for large-scale epidemiological studies. Moreover,
Bruker's IVDr Lipoprotein Subclass Analysis (B.I.LISA) and B.I.
Quant-PS 2. 0 will play an instrumental role in differentiating
health and disease state, and in monitoring the impact of various
treatments or dietary interventions. Bruker's NMR FoodScreener can
determine food quality, authenticity and nutrient stability. It
features extensive reference databases and covers targeted and
non-targeted tests for various food matrices, which will be
extended as part of the collaboration with the ANPC.
MS data will be analyzed using MetaboScape™ client-server
software, which seamlessly integrates flow-injection analysis (FIA)
extreme resolution MRMS workflows, quantitative analysis from the
'phenomics workhorse' impact-II QTOF mass spectrometers.
MetaboScape also integrates universal, molecule-specific collision
cross section prediction using machine learning (CCSPredict™) on
the timsTOF for 4D lipidomics.
Dr. Manfred Spraul, CTO of
Bruker's Applied, Industrial & Clinical magnetic resonance
division, commented: "Phenomics research continues to evolve and
offers fascinating insights into disease processes. With our
expertise in both mass spectrometry and nuclear magnetic resonance,
we are able to harness the unique and differentiated potential of
each technique and partner with researchers to combine the best
tools required for their metabolomics research."
Bruker Executive Vice President for Life Sciences Mass
Spectrometry, Rohan Thakur, PhD,
added: "This collaboration has the potential to deliver a
step-change in phenomics as it couples high-throughput MS/MS data
with novel collision cross section (CCS) aware 4D lipidomics and 4D
metabolomics on our timsTOF Pro platform. We are pleased that ANPC
has evaluated our 'phenomics workhorse' impact II QTOF, and found
it to be ultra-sensitive and stable for quantitation in
large-cohort studies. Finally, we are excited that Murdoch
University will adopt and further develop high-throughput FIA-MRMS
for identifying over one thousand metabolites in just a few
minutes, without the need for chromatography."
About Bruker Corporation (Nasdaq:
BRKR)
Bruker is enabling scientists to make
breakthrough discoveries and develop new applications that improve
the quality of human life. Bruker's high-performance scientific
instruments and high-value analytical and diagnostic solutions
enable scientists to explore life and materials at molecular,
cellular and microscopic levels. In close cooperation with our
customers, Bruker is enabling innovation, improved productivity and
customer success in life science molecular research, in applied and
pharma applications, in microscopy and nanoanalysis, and in
industrial applications, as well as in cell biology, preclinical
imaging, clinical phenomics and proteomics research and clinical
microbiology. For more information, please visit:
www.bruker.com.
Investor Contact:
Miroslava Minkova
Bruker
Director, Investor Relations & Corporate
Development
T: +1 (978) 663-3660
x1479
E:
Investor.Relations@bruker.com
Media Contact:
Murdoch
University
Carina Tan-Van
Baren
T: 0414 236 791
E:
carina.tan-vanbaren@murdoch.edu.au
Bruker Corporation
Dr. Thorsten
Thiel
VP of Group
Marketing
T: +49 (721) 5161–6500
E:
thorsten.thiel@bruker.com
1
https://www.murdoch.edu.au/research/institutes-centres/health-futures-institute/australian-national-phenome-centre
View original content to download
multimedia:http://www.prnewswire.com/news-releases/strategic-alliance-between-murdoch-university-and-bruker-supports-international-centre-of-excellence-in-metabolic-phenotyping-300922251.html
SOURCE Bruker Corporation